MEDTECH RECEIVES MARKETING AUTHORIZATION
IN AUSTRALIA FOR ROSA ROBOTIC SURGERY SYSTEM AND
SIGNS DISTRIBUTION AGREEMENT FOR AUSTRALIA AND NEW ZEALAND
Montpellier, France, May 18, 2015 – MEDTECH (Euronext, FR0010892950 – ROSA), a company
specialized in designing, developing and marketing innovative surgical robots, announced that it has
received official authorization to market its ROSA™ robot in Australia for minimally invasive surgical
procedures on the brain, and also spine surgery.
The Company also announced that it signed a distribution contract for Australia and New Zealand
with Surgicom, a company specializing in the distribution and marketing of innovative medical
devices, particularly in orthopedics. This agreement significantly reinforces Medtech’s geographical
coverage in the Asia-Pacific region through Surgicom’s various offices and commercial agents in
Sydney, Melbourne, Adelaide, Perth and Auckland. The entrance into the Australian and New
Zealand markets further supports Medtech’s strategy to expand its international sales organization.
“This is an important milestone in the company’s development and ongoing expansion of our market
opportunity. This authorization to market ROSA™ in Australia and the signing of a distribution
agreement with Surgicom is a reflection of our strategy to increase our commercial presence at
international level, including the Asia-Pacific region, where we already have strong momentum,”
commented Bertin Nahum, CEO and Founder of Medtech.
About MEDTECH
Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the
design, development and marketing of innovative robotic appliances to assist surgeons during their medicosurgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive
treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery
procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 Medtech received the « European Company of the Year Award” in the “robotic neurosurgery”
category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device
for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the « Révélation » prize in the Mediterranean Deloitte Technology Fast 50 Awards.
CONTACT MEDTECH
Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
INVESTORS
Corinne Puissant
Tel : +33 (0)1 53 67 36 77
[email protected]
PRESS
Alexandra Prisa (EU)
Melanie Sollid-Penton (US)
Tel. : +33(0)1 53 67 36 90 Tel : +1 646-536-7023
[email protected]
[email protected]